CLINICAL / SCIENTIFIC PRESENTATION AND PUBLICATION HIGHLIGHTS
The information contained in each post on this page was factually accurate on the date it was issued and posted.
American Association for Cancer Research (AACR) 2019 – STRO-001 Poster
A Phase 1 Open-Label, Safety, Pharmacokinetic, And Preliminary Efficacy Study Of STRO-001, An Anti-CD74 Antibody Drug Conjugate, In Patients With Advanced B-Cell Malignancies, NCT03424603
Sutro Biopharma to Present at the 18th Annual Needham Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 4, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that Bill Newell, Chief Executive Officer, will present at the 18th Annual Needham Healthcare Conference on Tuesday, April 9 at 4:50 p.m. ET at the Westin Grand Central...
Non-Confidential Corporate Presentation – JPM 2019
12th Biennial Ovarian Cancer Research Symposium – STRO-002 Abstract
Objectives: Folate receptor alpha (FolRa) is a cell-surface glycoprotein, highly expressed in ovarian and endometrial adenocarcinoma, and is thus a promising target for cancer therapy using antibody drug conjugates (ADCs). Most ADCs currently in development are...
12th Biennial Ovarian Cancer Research Symposium – STRO-002 Poster
Preclinical Activity and Safety of STRO-002, a Novel ADC Targeting Folate Receptor Alpha for Ovarian Cancer
American Society of Clinical Oncology (ASCO) 2018 – Poster
A PHASE 1 OPEN-LABEL, SAFETY, PHARMACOKINETIC, AND PRELIMINARY EFFICACY STUDY OF STRO-001, AN ANTI-CD74 ANTIBODY DRUG CONJUGATE, IN PATIENTS WITH ADVANCED B-CELL MALIGNANCIES, NCT03424603
American Association for Cancer Research (AACR) 2018 – STRO-002 Poster
Discovery and Activity of STRO-002, a Novel ADC Targeting Folate Receptor Alpha for Ovarian and Endometrial Cancer STRO-002 AACR 2018 Poster Final
American Association for Cancer Research (AACR) 2018 – STRO-002 Abstract
Generation and Activity of STRO-002, a novel ADC targeting Folate Receptor Alpha for Ovarian Cancer Folate receptor alpha (FolRa) is a glycosylphosphatidylinositol linked cell-surface glycoprotein that is highly expressed in serous and epithelial ovarian cancer...
Society for Gynecologic Oncology (SGO) 2018 – STRO-002 Abstract
Preclinical Activity and Safety of STRO-002, a novel ADC targeting Folate Receptor Alpha for Ovarian Cancer Objectives: Folate receptor alpha (FolRa) is a cell-surface glycoprotein, highly expressed in ovarian and endometrial adenocarcinoma, that is a promising target...